Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma

Vijaya R Bhatt, Smith Giri, Vivek Verma, Sumit Dahal, Binay K. Shah, Ranjan Pathak, Robert G Bociek, Julie Marie Vose, James Olen Armitage

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. Results: Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years. Conclusion: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.

Original languageEnglish (US)
Pages (from-to)1565-1575
Number of pages11
JournalFuture Oncology
Volume12
Issue number13
DOIs
StatePublished - Jul 2016

Fingerprint

Hodgkin Disease
Acute Myeloid Leukemia
Survivors
Survival
Epidemiology
Databases
Transplants
Therapeutics
Population

Keywords

  • Hodgkin lymphoma
  • acute myeloid leukemia
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma. / Bhatt, Vijaya R; Giri, Smith; Verma, Vivek; Dahal, Sumit; Shah, Binay K.; Pathak, Ranjan; Bociek, Robert G; Vose, Julie Marie; Armitage, James Olen.

In: Future Oncology, Vol. 12, No. 13, 07.2016, p. 1565-1575.

Research output: Contribution to journalArticle

Bhatt VR, Giri S, Verma V, Dahal S, Shah BK, Pathak R et al. Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma. Future Oncology. 2016 Jul;12(13):1565-1575. https://doi.org/10.2217/fon-2016-0048
Bhatt, Vijaya R ; Giri, Smith ; Verma, Vivek ; Dahal, Sumit ; Shah, Binay K. ; Pathak, Ranjan ; Bociek, Robert G ; Vose, Julie Marie ; Armitage, James Olen. / Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma. In: Future Oncology. 2016 ; Vol. 12, No. 13. pp. 1565-1575.
@article{e25b1b06f4c74096b322ed736f6434e6,
title = "Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma",
abstract = "Background: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. Results: Patients with sAML (median age: 47 years; 82{\%} <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years. Conclusion: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.",
keywords = "Hodgkin lymphoma, acute myeloid leukemia, survival",
author = "Bhatt, {Vijaya R} and Smith Giri and Vivek Verma and Sumit Dahal and Shah, {Binay K.} and Ranjan Pathak and Bociek, {Robert G} and Vose, {Julie Marie} and Armitage, {James Olen}",
year = "2016",
month = "7",
doi = "10.2217/fon-2016-0048",
language = "English (US)",
volume = "12",
pages = "1565--1575",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "13",

}

TY - JOUR

T1 - Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma

AU - Bhatt, Vijaya R

AU - Giri, Smith

AU - Verma, Vivek

AU - Dahal, Sumit

AU - Shah, Binay K.

AU - Pathak, Ranjan

AU - Bociek, Robert G

AU - Vose, Julie Marie

AU - Armitage, James Olen

PY - 2016/7

Y1 - 2016/7

N2 - Background: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. Results: Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years. Conclusion: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.

AB - Background: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. Results: Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years. Conclusion: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.

KW - Hodgkin lymphoma

KW - acute myeloid leukemia

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84975824221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975824221&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0048

DO - 10.2217/fon-2016-0048

M3 - Article

C2 - 27079926

AN - SCOPUS:84975824221

VL - 12

SP - 1565

EP - 1575

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 13

ER -